Company news
Canbridge Pharmaceuticals Inc. (HKEX:1228) news
Canbridge Pharmaceuticals Inc. news releases on 6ix. Latest, Aug 18, 2026: CANbridge Announces NHIA Reimbursement Approval of Livmarli for Alagille Syndrome…
Press releases & updates
CANbridge Announces NHIA Reimbursement Approval of Livmarli for Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Taiwan
August 18, 2026
CANbridge Announces Strategic Partnership and Investment from Baheal to Strengthen Commercialization of Rare Disease Products
August 14, 2025
CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate
October 29, 2024
CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
August 19, 2024
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
October 18, 2023
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme in China Reaches Full Enrollment
March 29, 2023
CANbridge Pharmaceuticals Announces CAN008 Phase 1/2 Glioblastoma Multiforme Abstract Accepted by the ESMO Sarcoma and Rare Cancers Congress
March 14, 2023
CANbridge Announces Financial Results and Corporate Updates for Six Months Ended June 30, 2022
August 25, 2022
CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases
July 7, 2022
CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended December 31, 2021
March 24, 2022
CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Accepted by China's National Medical Products Administration
January 19, 2022
CANbridge Pharmaceuticals - The Chinese Red Cross Foundation Rare Disease Mutual Assistance Fund Officially Launches
December 21, 2021